Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273-Reference-Cited by-同舟云学术

Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273

Published:2022-04-27 Issue:2 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Grunau Brian¹²³^ORCID,Golding Liam⁴,Prusinkiewicz Martin A.⁵,Asamoah-Boaheng Michael²⁶^ORCID,Armour Richard³,Marquez Ana Citlali⁷⁸,Jassem Agatha N.⁷⁸,Barakauskas Vilte⁷,O’Brien Sheila F.⁹^ORCID,Drews Steven J.⁹¹⁰^ORCID,Haig Scott³,Lavoie Pascal M.⁵,Goldfarb David M.⁷^ORCID

Affiliation:

1. Centre for Health Evaluation & Outcome Sciences, University of British Columbia, Vancouver, British Columbia, Canada

2. Department of Emergency Medicine, University of British Columbia, Vancouver, British Columbia, Canada

3. British Columbia Emergency Health Services, Vancouver, British Columbia, Canada

4. Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada

5. Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada

6. Faculty of Medicine, Clinical Epidemiology, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada

7. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada

8. Public Health Laboratory, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada

9. Canadian Blood Services, Ottawa, Ontario, Canada

10. Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada

Abstract

The BNT162b2 and mRNA-1273 mRNA SARS-CoV-2 vaccines have demonstrated high efficacy for preventing short-term COVID-19. However, comparative long-term effectiveness is unclear, especially pertaining to the Delta variant.

Funder

Government of Canada

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.02702-21

Reference24 articles.

1. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

2. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

3. World Health Organization. 2021. COVID-19 weekly epidemiological update. Edition 55. World Health Organization Geneva Switzerland. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-august-2021. Accessed August 31 2021.

4. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada

5. World Health Organization. 2021. COVID-19 weekly epidemiological update. Edition 70 (December 14 2022). World Health Organization Geneva Switzerland. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---11-january-2022. Accessed January 11 2022.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The relationship between the number of COVID-19 vaccines and infection with Omicron ACE2 inhibition at 18-months post initial vaccination in an adult cohort of Canadian paramedics;Access Microbiology;2023-11-01

2. Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021;Microbiology Spectrum;2023-08-17

3. Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses;Microbiology Spectrum;2022-10-26